In the cases studied in this report, we observed upregulation of not only TIM-3 on T cells but Galectin-9 on tumour cells in the case of Kras mutant tumours, indicating that resistance to PD-1 therapy can be driven by coordinated interactions among the tumour and neighbouring immune cells. The gene discussed is HAVCR2; the disease is neoplasm.